Study Overview: The study aims to find out if a medication called eptinezumab can help reduce the number of migraine days in kids who have episodic migraines. Migraines are severe headaches that sometimes come with a warning sign called an aura, like seeing flashing lights.

Eligibility: To join, participants need to have a history of migraines for at least 6 months and must track their headaches in a diary for 28 days. This diary should show that they have 14 or fewer headache days, with at least 4 being migraine days. Certain headache types like chronic tension-type or cluster headaches will exclude participants, as well as other health conditions that affect the brain or mental health that are not well-controlled.

• The study involves a 28-day screening period with a headache diary.
• Participants will be given eptinezumab to see its effects on their migraines.
• Excludes those with other severe headache types or untreated mental health issues.